【瞩目】石药1类新药来袭,猛攻220亿潜力市场

米内网
Oct 31, 2025

精彩内容近日,CDE官网显示,石药集团的化药1类新药SYH2070注射液获得临床试验默示许可,拟用于高脂血症。米内网数据显示,2024年中国三大终端六大市场血脂调节剂化药销售额超220亿元,2025H1同比增长10.14%。今年以来,石药已有10款化药1类新药获批临床,其中7款为首次获批。来源:CDE官网SYH2070注射液是由石药集团开发的化药1类创新药,拟用于高脂血症。米内网数据显示,该新药的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10